Compound Radar

Quest Diagnostics Incorporated (DGX) Stock Analysis

Price $235.50
Market cap $25.99B
Next earnings Oct 20, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

67
67/100 Good Quality
  • Financial Health 75
  • Profitability 60
  • Business Quality 60
  • Balance Sheet 55
  • Cash Flow 80

Why this rating?

Health 67/100 — Good Quality

Strongest Cash Flow 80/100
Softest Balance Sheet 55/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Quest Diagnostics Incorporated (DGX) is a Diagnostics & Research company in the Healthcare sector. Compound Radar rates Quest Diagnostics Incorporated 67/100 (Good Quality) due to solid business quality, steady revenue growth, and manageable leverage.

Investment profile

  • Quality Moderate
  • Growth Moderate
  • Balance Sheet Adequate
  • Valuation Fair

Financial highlights

Valuation

  • P/E 25.03
  • Forward P/E 19.53
  • PEG 1.84
  • EV/Revenue 2.8

Profitability

  • Revenue Growth 10.2%
  • Gross Margin 33.2%
  • Operating Margin 15.2%
  • Net Margin 9.2%
  • ROE 14.6%

Financial strength

  • Cash $626.00M
  • Debt $6.40B
  • Net Cash $-5.78B
  • Free Cash Flow $1.36B
  • Current Ratio 1.59

Similar companies

Peers in Diagnostics & Research, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Diagnostics & Research →

FAQ

How Compound Radar scores and tracks Quest Diagnostics Incorporated (DGX).

View Methodology & FAQ →